← Every company
CRISPR Therapeutics AG Patents
What CRISPR Therapeutics AG has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
CRSP on carbonthat →Filings on file
31
Granted
1
Still pending
30
Filed under
2 names
31 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| UNIVERSAL DONOR CELLSA61K 35/39, C12N 5/0678, C12N 15/85, A61P 3/10, A61K 35/12, A61K 35/28, A61K 35/545, A61K 38/1709, C07K 14/70539, C07K2319/02, C07K2319/03, C12N 5/0606, C12N 5/0607, C12N 5/0696, C12N 5/10, C12N 5/16, C12N2506/02, C12N2506/45, C12N2510/00Filed as CRISPR Therapeutics AG2025-08-18Alireza Rezania | pending |
| RT EDITING COMPOSITIONS AND METHODSA61K 48/005, C12Y 207/07049, C12N2310/20, A61P 5/00, A61P 11/00, A61K 9/1272, A61K 9/5123, C07K2319/09, C07K2319/80, C12N 9/1276, C12N 9/22, C12N 15/00, C12N 15/111, C12N 15/1137, C12N 15/86, C12N 15/88, C12N2320/34, C12N2750/14143, C12N2800/22, C12N2830/48Filed as CRISPR Therapeutics AG2025-02-26Christof Fellmann | pending |
| GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCEC07K 14/70578, C12N 5/0636, C12N2310/20, A61K2239/48, A61K2239/31, A61K2239/56, A61K2239/38, A61K2239/54, A61K 40/4232, A61K 40/4251, A61K 40/4215, A61K 40/4211, A61K 40/31, A61K 40/50, A61K 40/11, C12N 9/226, A61K 38/00, A61K 48/00, C07K 14/7051, C07K 14/70521, C07K 14/70575, C07K 14/70596, C07K 14/71, C07K 16/2803, C07K 16/2875, C07K 16/2878, C07K 16/30, C07K2317/622, C07K2319/02, C07K2319/03, C12N 5/16, C12N 9/22, C12N 15/111, C12N 15/113, C12N 15/1138, C12N 15/86, C12N 15/907, C12N2310/315, C12N2310/321, C12N2310/3521, C12N2510/00, C12N2750/14143Filed as CRISPR Therapeutics AG2025-02-18Mary-Lee Dequeant | pending |
| GENE-EDITED NATURAL KILLER CELLSA61K 35/17, C12N 5/0646, A61P 35/00, A61K2239/55, A61K 40/4202, A61K 40/15, A61K 40/31, C07K 14/5443, C07K 14/7051, C07K 14/7155, C12N2510/00Filed as CRISPR Therapeutics AG2025-01-30Alireza Rezania | pending |
| METHODS AND COMPOSITIONS FOR TREATING CANCERC07K 16/2878, C12N 5/0636, C12N2310/20, A61K 47/6849, A61P 35/00, A61K2039/86, A61K2039/852, A61K2039/892, A61K2039/868, A61K2039/804, A61K2239/28, A61K2239/31, A61K2239/38, A61K 40/4232, A61K 40/4215, A61K 40/4211, A61K 40/32, A61K 40/31, A61K 40/50, A61K 40/421, A61K 40/11, C12N 9/226, A61K 35/17, A61K 38/00, A61K 51/1027, A61K2039/505, A61K2039/5156, A61K2121/00, A61K2300/00, C07K 14/7051, C07K 14/70517, C07K 14/70521, C07K 14/70539, C07K 14/70578, C07K 16/2803, C07K 16/2875, C07K2317/565, C07K2317/622, C07K2317/74, C07K2317/76, C07K2319/02, C07K2319/03, C07K2319/30, C07K2319/33, C12N 9/22, C12N 15/11, C12N 15/86, C12N2510/00, C12N2750/14143, C12N2800/80Filed as CRISPR Therapeutics AG2025-01-14Jonathan Alexander Terrett | pending |
| MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSISA61K 48/0058, C12N 15/102, C12N2310/20, C12N 9/224, A61K 9/0019, A61K 48/005, A61K 48/0066, A61K 48/0075, C12N 5/0663, C12N 5/067, C12N 15/1138, C12N 15/907Filed as CRISPR Therapeutics AG2025-01-05Roman Lvovitch Bogorad | pending |
| MESSENGER RNA ENCODING CAS9 FOR USE IN GENOME-EDITING SYSTEMSC12N 9/226, C12N 15/111, C12N2310/20, A61K 9/5123, A61K 31/7088, A61K 48/00, A61K 48/005, C12N 9/22, C12N 15/102, C12N 15/11, C12N 15/88, C12N 15/907, C12N2310/335, C12N2320/32, C12N2800/80Filed as CRISPR THERAPEUTICS AG2025-01-03Christian Cobaugh | pending |
| BASE EDITING PROTEINS AND USES THEREOFC12N 9/226, C12N 9/22, C12N2310/20, A61P 35/00, A61K 40/4232, A61K 40/4224, A61K 40/31, A61K 40/11, A61K 31/7105, A61K 38/465, A61K 38/50, A61K2039/505, A61K2039/5156, C07K 16/2875, C07K2319/00, C07K2319/03, C07K2319/09, C07K2319/33, C07K2319/70, C12N 5/0636, C12N 9/78, C12N 15/11, C12N 15/113, C12N 15/62, C12N 15/907, C12N2510/00, C12Y 305/04005Filed as CRISPR THERAPEUTICS AG2024-12-19John KULMAN | pending |
| METHODS AND COMPOSITIONS FOR IN VIVO EDITING OF STEM CELLSA61K 48/0058, C12N 15/86, C12N2310/20, C12N 9/226, C12N 5/0647, C12N 15/102, C12N 15/11, C12N 15/113, C12N 15/1138, C12N 15/907, C12N2510/00, C12N2750/14143, C12N2800/40Filed as CRISPR THERAPEUTICS AG2024-12-19Kyungah MAENG | pending |
| CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO CD117A61K 40/31, C07K 16/2803, A61P 35/00, A61K2239/13, A61K 40/4216, A61K 40/4215, A61K 40/11, A61K 35/14, A61K2039/5156, C07K 14/7051, C07K 14/70517, C07K 14/70521, C07K 14/70575, C07K2317/22, C07K2317/565, C07K2317/569, C07K2317/622, C07K2317/73, C07K2319/02, C07K2319/03, C07K2319/33, C12N 5/0634, C12N 5/10, C12N 15/625, C12N2510/00Filed as CRISPR THERAPEUTICS AG2024-12-19Jason SAGERT | pending |
| CD117-TARGETING NANOPARTICLES FOR USE IN DRUG DELIVERYA61K 47/6913, C07K 16/2803, C12N2310/20, A61K 47/6849, C12N 9/222, C07K2317/33, C07K2317/35, C07K2317/40, C07K2317/565, C07K2317/567, C07K2317/569, C07K2317/77, C07K2317/92, C07K2317/94, C07K2319/01, C07K2319/02, C07K2319/21, C12N 15/11, C12N 15/111, C12N 15/88, C12N2320/32Filed as CRISPR THERAPEUTICS AG2024-12-19Megan D. WARNER | pending |
| CHIMERIC ANTIGEN RECEPTOR TARGETING GPC-3 AND IMMUNE CELLS EXPRESSING SUCH FOR THERAPEUTIC USESA61K 35/17, C07K 16/303, A61P 35/00, A61K2239/13, A61K2239/53, A61K2239/21, A61K2239/22, A61K 40/4261, A61K 40/4202, A61K 40/31, A61K 40/11, C12N 9/226, C07K 14/7051, C07K 14/70517, C07K 14/70521, C07K 14/70539, C07K 14/70578, C07K 14/71, C07K 14/82, C07K2317/565, C07K2317/569, C07K2319/00, C07K2319/03, C07K2319/33, C12N 5/0636, C12N 9/104, C12N 9/22, C12N2510/00, C12Y 203/02Filed as CRISPR THERAPEUTICS AG2024-12-06Jason Sagert | pending |
| GENE-EDITED NATURAL KILLER CELLSC12N 5/0646, C12N2310/20, A61P 35/00, A61K2239/55, A61K2239/53, A61K2239/31, A61K 40/35, A61K 40/13, A61K 40/4261, A61K 40/30, A61K 40/42, A61K 40/4202, A61K 40/15, A61K 40/31, A61K 40/50, A61K 40/11, A61K 9/0019, A61K 35/17, C07K 14/5443, C07K 14/7051, C07K 14/70535, C07K 14/70539, C07K 14/70596, C07K 14/7155, C07K 14/8121, C07K2319/00, C12N 5/0606, C12N 5/0635, C12N 5/0636, C12N 5/0647, C12N 5/0696, C12N 9/22, C12N 15/1138, C12N 15/62, C12N 15/63, C12N2506/45, C12N2510/00Filed as CRISPR THERAPEUTICS AG2024-11-30Valentin SLUCH | pending |
| COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLSC12N 5/0646, C12N 5/0696, A61K 35/17, C12N2501/115, C12N2501/125, C12N2501/145, C12N2501/155, C12N2501/16, C12N2501/165, C12N2501/2303, C12N2501/2307, C12N2501/2315, C12N2501/26, C12N2501/415, C12N2501/727, C12N2506/00, C12N2506/02, C12N2506/03, C12N2506/45, C12N2510/00Filed as CRISPR THERAPEUTICS AG2024-11-30Viktoriia KYRYCHENKO | pending |
| ANTI-PTK7 IMMUNE CELL CANCER THERAPYC07K 14/70521, C07K 16/40, C12N 5/0636, A61P 35/00, A61K2039/86, A61K2039/852, A61K2039/892, A61K2239/55, A61K2239/59, A61K2239/49, A61K2239/38, A61K2239/54, A61K 40/4251, A61K 40/4211, A61K 40/31, A61K 40/11, A61K 35/17, A61K2039/505, A61K2121/00, A61K2300/00, C07K 14/7051, C07K 14/70539, C07K 14/70575, C07K 14/70578, C07K2317/56, C07K2317/565, C07K2317/622, C07K2319/00, C07K2319/02, C07K2319/03, C12N 15/11, C12N 15/86, C12N2510/00, C12N2750/14143Filed as CRISPR THERAPEUTICS AG2024-11-14Jonathan Alexander Terrett | pending |
| RT EDITING COMPOSITIONS AND METHODSFiled as CRISPR Therapeutics AG2024-11-11Christof Fellmann | pending |
| GUIDE DESIGN AND OFF-TARGET SEARCHESG16B 30/10, C12N2310/20, C12N 9/226, C12N 15/11, C12N 15/907, G16B 35/10Filed as CRISPR THERAPEUTICS AG2024-10-25John Michael TOOMEY | pending |
| METHODS AND COMPOSITIONS FOR TREATING LIPOPROTEIN-RELATED DISEASESA61K 38/465, C12N 15/113, C12N2310/20, A61P 9/00, C12N 9/226, A61K 9/5123, A61K 31/7088, A61K 38/00, A61K 48/0058, C12N 15/11, C12N 15/111, C12N 15/907Filed as CRISPR THERAPEUTICS AG2024-09-20Sanjay D'SOUZA | pending |
| METHODS AND COMPOSITIONS FOR TREATING LIPOPROTEIN-RELATED DISEASESA61K 38/465, C12N 15/113, C12N2310/20, A61P 9/00, C12N 9/226, A61K 9/5123, A61K 31/7088, A61K 38/00, A61K 48/0058, C12N 15/11, C12N 15/111, C12N 15/907Filed as CRISPR THERAPEUTICS AG2024-09-20Sanjay D'SOUZA | pending |
| METHODS AND COMPOSITIONS FOR TREATING LIPOPROTEIN-RELATED DISEASESA61K 38/465, C12N 15/113, C12N2310/20, A61P 9/00, C12N 9/226, A61K 9/5123, A61K 31/7088, A61K 38/00, A61K 48/0058, C12N 15/11, C12N 15/111, C12N 15/907Filed as CRISPR THERAPEUTICS AG2024-09-20Sanjay D'SOUZA | pending |
| MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENEC12N 15/1137, C12N2310/20, C12N 9/226, C12N 15/88, C12N2310/315, C12N2310/321, C12Y 203/01037Filed as CRISPR Therapeutics AG2024-07-21Mary-Lee Dequeant | 12644123 |
| METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONSC12N 9/226, C12N 15/113, C12N2310/20, A61P 3/00, C12N 15/11Filed as CRISPR Therapeutics AG2024-07-11Yi-Shan Chen | pending |
| METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONSC12N 9/226, C12N 15/113, C12N2310/20, A61P 3/00, C12N 15/11Filed as CRISPR Therapeutics AG2024-07-11Yi-Shan Chen | pending |
| RT EDITING COMPOSITIONS AND METHODSFiled as CRISPR Therapeutics AG2024-05-20Christof Fellmann | pending |
| COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLSC07K 16/2896, A61K 47/6831, A61K 47/6817, A61K 47/6849, A61P 37/06, A61P 35/00, A61K 35/545, A61K 38/00, A61K2035/124, A61K2039/505, C07K 7/64, C07K 16/2803, C07K2317/21, C07K2317/52, C07K2317/55, C07K2317/71, C07K2317/73, C07K2317/92, C07K2317/94Filed as CRISPR THERAPEUTICS AG2024-04-04Bradley R. Pearse | pending |
| MASKED CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO TYROSINE-PROTEIN KINASE LIKE 7 (PTK7) AND IMMUNE CELLS EXPRESSING SUCHC07K 14/705, C07K 16/40, A61P 35/00, A61K2239/31, A61K2239/38, A61K2239/54, A61K 40/4251, A61K 40/31, A61K 40/11, A61K 35/17, A61K 38/00, A61K2039/505, A61K2039/5156, A61K2039/5158, C07K 7/08, C07K 14/47, C07K 14/7051, C07K 14/70517, C07K 14/70521, C07K 14/70578, C07K 16/3046, C07K2317/622, C07K2317/72, C07K2317/73, C07K2317/76, C07K2317/92, C07K2319/02, C07K2319/03, C07K2319/30, C07K2319/33, C07K2319/50, C12N 5/0636, C12N 15/62, C12N2510/00, C12Y 207/01112Filed as CRISPR Therapeutics AG2024-03-04Jason Sagert | pending |
| RT EDITING COMPOSITIONS AND METHODSFiled as CRISPR Therapeutics AG2024-02-27Christof Fellmann | pending |
| COMPOSITIONS AND METHODS FOR GENE EDITINGC12N 15/111, C12N 15/86, C12N2310/20, C12N 9/226, C07K 14/515, C12N 7/00, C12N 9/22, C12N 15/1136, C12N2750/14143, C12N2800/80Filed as CRISPR THERAPEUTICS AG2024-02-16Ante Sven Lundberg | pending |
| GENE-EDITED NATURAL KILLER CELLSFiled as CRISPR Therapeutics AG2024-01-31Alireza Rezania | pending |
| MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENEFiled as CRISPR Therapeutics AG2024-01-24Mary-Lee Dequeant | pending |
| MATERIALS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1AC12N 15/102, C12N 15/907, C12N2310/20, C12N 9/226, A61K 38/00, C12N 9/16, C12N 15/11, C12N2800/80, C12Y 301/03009Filed as CRISPR THERAPEUTICS AG2024-01-08Chad Albert COWAN | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on CRSP
Company overviewEverything on CRSP in one place, with the price.SEC filingsWhat CRSP's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat CRSP's own officers and directors buy and sell.Planned salesSales CRSP insiders have filed notice of.Executive payWhat CRSP awarded its chief executive, and what it became.LobbyingWhat CRSP spends lobbying Congress, and on what.